Luz Hammershaimb

Immunology and Microbiology · Life Sciences

13h-index2.4kcitations31works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and Retrovirus Studies(10), Lung Cancer Treatments and Mutations(8), Viral-associated cancers and disorders(8), Colorectal Cancer Treatments and Studies(6), Lung Cancer Research Studies(6)

Publications31 total

Data from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Data from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma
Journal of Immunotherapy·2010· 23 cited
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α<sub>v</sub>β<sub>3</sub>, ± dacarbazine in patients with stage IV metastatic melanoma
Cancer·2010· 186 citedOpen Access
EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Clinical Cancer Research·2009· 58 citedOpen Access
EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.
Blood·2007· 8 cited
Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
Investigational New Drugs·2007· 100 cited
Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.
Blood·2005· 25 cited
Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Clinical Cancer Research·2005· 157 cited
Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease
Journal of Immunotherapy·2005· 13 cited
Phase I trial of siplizumab in CD2-positive lymphoproliferative disease
Journal of Clinical Oncology·2005· 10 cited
Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
PubMed·2003· 84 cited
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study
Annals of Oncology·2002· 27 citedOpen Access
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
Annals of Oncology·2002· 27 cited
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer
Annals of Oncology·2002· 12 cited
Phase III randomized double blind placebo controlled trial of carboplatin and radiation therapy ± amifostine in patients with head and neck cancer
International Journal of Radiation Oncology*Biology*Physics·2001· 4 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

John E. Janik(11), Thomas A. Waldmann(10), Karen Kaucic(9), Deirdre O’Mahony(9), Maryalice Stetler‐Stevenson(9), Helen Matthews(8), Stefania Pittaluga(8), Paul S. Albert(8), Margaret R. Brown(7), Thomas A. Fleisher(7), Mark Raffeld(7), Dirk J. Reitsma(7), John C. Morris(5), Frank V. Fossella(4), F. Gamza(4), Carl Pinsky(3), Nicholas J. Petrelli(3), Yehuda Z. Patt(3), J. Bérille(3), John C. Morris(3)